Research & Markets: GlaxoSmithKline - Have an Estimated Seven Per Cent Share of the Worlds Pharmaceutical Market.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47235 ) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: GlaxoSmithKline Prospects to 2010 to their offering Headquartered in the UK and with operations based in the US, GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) is one of the leading ethical pharmaceutical companies in the industry with an estimated seven per cent share of the worlds pharmaceutical market. GlaxoSmithKline was formed in 2000 as a result of the merger of Glaxo Wellcome and SmithKline Beecham. In 2005, it was the worlds second largest research-based pharmaceutical company based on pharmaceutical sales. GSK employs over 100,000 people in 116 countries, with over 40,000 of these in sales and marketing, the largest sales force in the industry. GSK has a broad portfolio, with projects in the fields of respiratory, central nervous system, anti-infectives, metabolic disorders, oncology, cardiovascular and urogenital. In addition, GSK has an extensive vaccines portfolio. According to GSK, it supplied one quarter of the worlds vaccines and by the end of 2005 and had a further 25 in clinical development. The company has a leading position in genomics/genetics and new drug discovery technologies. GSK also has a Consumer Healthcare portfolio comprising over-the-counter medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. Current Growth Drivers GSKs key growth drivers in 2005 were: Advair which maintained its strong growth in the US and Europe with sales of [pounds sterling]1,687 million and [pounds sterling]1,033 million, respectively. Flonase for perennial rhinitis Rhinitis Definition Rhinitis is inflammation of the mucous lining of the nose. Description Rhinitis is a nonspecific term that covers infections, allergies, and other disorders whose common feature is the location of their symptoms. also showed strong growth in the US. Wellbutrin XL performed exceptionally well, helping to offset the decline in sales of the immediate-release products due to generic competition. Antivirals grew by 10 per cent, with HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. products up by 2 per cent. Sales of Valtrex, for herpes, grew by 26 per cent driven by patients switching to suppression therapy. Sales of Avandia/Avandamet increased by 14 per cent, whilst antibacterial sales declined by 27 per cent as a result of generic competition that began in the third quarter 2002. Coreg sales increased by 33 per cent to [pounds sterling]568 million reflecting the benefit of its wide range of indications. Vaccines also performed well in 2005, growing by 26 per cent, reflecting a strong performance of Pediarix and Fluarix. Products Mentioned Include: Advair Flonase Wellbutrin XL Antivirals Avandia/Avandamet Pediarix Fluarix Summary Pharmaceutical company intelligence reports provide a full review of the companys activities together with five-year sales forecasts for its key products. The companys financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the companys product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Companies Mentioned - Adherex Technologies Inc - Adolor Corporation - Aeras Global TB Vaccine Foundation - Antigenics Inc - Aphton Corporation - Asahi Chemical Industry Co - Astellas Pharma - AVANT Immunotherapeutics Inc - Bavarian Nordic - Bayer - bioMerieux-Pierre Fabre - Bioseek Inc - Biovail Corporation International - Boehringer Ingelheim - Bristol-Myers Squibb - ChemoCentryx - Crucell NV/Walter Reed Army Institute of Research - Cytokinetics Inc - Daiichi Sankyo - Dainippon Sumitomo Pharma - Exelixis Inc - Galapagos nv - Genstruct Inc - Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Inc (HGS HGS Human Genome Sciences, Inc. (Rockville, Maryland) HGS Heads Up Guidance System HGS Halifax Grammar School (Halifax, Canada) HGS Hangars HGS Heckmondwike Grammar School (UK) ) - Japan Tobacco (JT) - Kissei Pharmaceutical - Ludwig Institute for Cancer Research The Ludwig Institute for Cancer Research (LICR) is a global non-profit medical research institute that undertakes laboratory and clinical research into cancer, conducting and sponsoring its own early-phase clinical trials to investigate its discoveries. (LICR LICR Ludwig Institute for Cancer Research ) - MedImmune Inc/Aviron Inc - Merck & Co - Millennium Pharmaceuticals Inc - Neurocrine Biosciences Inc - NeuroSearch A/S - NiKem Research srl - Novo Nordisk - Organon - Pharmacopeia pharmacopeia /phar·ma·co·pe·ia/ (-ko-pe´ah) an authoritative treatise on drugs and their preparations. See also USP. pharmacopei´al United States Pharmacopeia see under U. Inc - Pozen Inc - Ranbaxy Laboratories Limited - Roche - Shionogi - Sirna Therapeutics Inc - SkyePharma PLC - Taiho Pharmaceutical Company Ltd - Tanabe - Teva Pharmaceutical Industries Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ), NASDAQ: TEVA is an international pharmaceutical company headquartered in Ltd - The International AIDS Vaccine Initiative A public-private partnership dedicated to producing a preventive vaccine against HIV infection, suitable for use in the most affected developing countries. To date, no such vaccine exists but scientific consensus suggests that its development is feasible. (IAVI IAVI International AIDS Vaccine Initiative ) - Theravance Inc - Unigene Laboratories Inc - Vertex Pharmaceuticals Inc - Vitae Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/reports/c47235 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion